Coronavirus News Archive

HHS and DOD Announce $12.7 Million Contract with InBios International to Boost U.S. Production of Rapid COVID-19 Rests

The U.S. Department of Health and Human Services (HHS) and the U.S. Department of Defense (DOD) jointly announced a $12.7 million contract with InBios International Inc., of Seattle, to expand domestic production capacity for two rapid point-of-care tests for SARS-CoV-2, the virus that causes COVID-19.

Supply kits to help healthcare workers who will be administering COVID-19 vaccines

In support of Operation Warp Speed (OWS), the Trump Administration is preparing to provide ancillary supply kits to help healthcare workers who will be administering COVID-19 vaccines. Each kit will contain enough supplies to administer up to 100 doses of vaccine and will include: needles, syringes alcohol prep pads, surgical masks and face shields for vaccinators, covid-19 vaccination record cards for vaccine recipients, and needle information card.
“With the Strategic National Stockpile and McKesson putting together the vaccine kits with needles, syringes, and PPE needed to vaccinate every American, we’ll ensure that safe and effective vaccines can reach Americans and start saving lives as soon as possible.” - HHS Secretary Alex Azar.

Donating plasma, blood, supplies and equipment

Donate COVID-19 Plasma
• If you have fully recovered from COVID-19, you may be able to help patients currently fighting the infection by donating your plasma. Because you fought the infection, your plasma now contains COVID-19 antibodies. These antibodies provided one way for your immune system to fight the virus when you were sick, so your plasma may be able to be used to help others fight off the disease. Learn more here.
• To find where you can donate source plasma, visit donatingplasma.org.

Donate Blood
• The COVID-19 pandemic has caused unprecedented challenges to the U.S. blood supply. Donor centers have experienced a dramatic reduction in donations due to the implementation of social distancing and the cancellation of blood drives. Blood is needed every day to provide lifesaving treatments to a variety of patients. You can help ensure that blood continues to be available for patients by finding a blood donor center near you to schedule your donation. Learn more here.
• To find where you can donate blood, visit aabb.org.

Donate Supplies and Equipment
• If you represent a business that would like to donate medical supplies, equipment or pharmaceuticals, please provide details on what you would like to give: http://www.fema.gov/covid19offers

White House update

By the end of this week, the U.S. Department of Health and Human Services (HHS) will have delivered 125 million masks to support safe school reopening. These masks support students, teachers, and staff in public and private schools, with an emphasis on low-income or other high-needs students and schools providing in-person instruction. Learn more: https://www.phe.gov/Preparedness/news/Pages/125-Million-Masks.aspx
• “The President continues to support extraordinary measures to safely reopen America’s schools,” said Dr. Robert Kadlec, HHS Assistant Secretary for Preparedness and Response. “The school mask program exemplifies the Administration’s on-going commitment to support states and territories as they limit the spread of COVID-19, while also ensuring that children, teachers, and school staff have essential resources that will keep them safe throughout the school year.”
• For more information on the President’s school mask program, visit the ASPR website: https://www.phe.gov/facecovering/Pages/cloth-face-masks-in-school.aspx
• For more information about how the cloth masks are being distributed, view the state-by-state distribution plan: https://www.phe.gov/facecovering/Pages/State-Allocations.aspx

Protein Mapping Study Reveals Valuable Clues for COVID-19 Drug Development

One way to fight COVID-19 is with drugs that directly target SARS-CoV-2, the novel coronavirus that causes the disease. That’s the strategy employed by remdesivir, the only antiviral drug currently authorized by the U.S. Food and Drug Administration to treat COVID-19. Another promising strategy is drugs that target the proteins within human cells that the virus needs to infect, multiply, and spread.

I'm the FDA point person on COVID-19 vaccines. We'll make sure they're safe and effective.

In phase 3 trials that are designed to show whether a vaccine really works, neither people receiving the vaccine nor those assessing the outcome know who received the vaccine or the inactive comparator. Only an independent monitoring group can access this information, when necessary, to protect the safety of trial participants. To evaluate efficacy, the number of clinical events, such as getting the disease that the vaccine is supposed to prevent, are counted in a systematic pre-determined manner.

States report plans for distributing rapid, point of care tests

As part of the Trump Administration’s comprehensive national effort to fight the COVID-19 pandemic, HHS purchased 150 million Abbott BinaxNOW rapid tests from Abbott. This week, states have begun to report back where they are choosing to distribute the rapid, point of care tests. Of the states who have provided preliminary reports, use of the BinaxNOW allocations are largely being deployed to local health departments, K-12 schools and institutes of higher education, nursing homes, hospitals and correctional facilities.

Coronavirus Food Assistance Program 2

President Trump and U.S. Secretary of Agriculture Sonny Perdue announced on September 17 that USDA will implement an expansion of the Coronavirus Food Assistance Program. Coronavirus Food Assistance Program 2, CFAP 2, will provide producers with financial assistance that gives them the ability to absorb some of the increased marketing costs associated with the COVID-19 pandemic.
• CFAP 2 follows the first round of CFAP, which had an application period of May 26 through September 11. You can learn more about USDA’s initial Coronavirus Food Assistance Program by visiting farmers.gov/cfap1.
• Producers can apply for assistance beginning Sept. 21, 2020. Applications will be accepted through Dec. 11, 2020.
• Additional information and application forms can be found at farmers.gov/cfap. Documentation to support the producer’s application and certification may be requested. All other eligibility forms, such as those related to adjusted gross income and payment information, can be downloaded from farmers.gov/cfap/apply.
• For existing FSA customers, including those who participated in CFAP 1, many documents are likely already on file. Producers should check with FSA county office to see if any of the forms need to be updated.
• In addition to CFAP 2, USDA has other programs and services available to farmers impacted by the coronavirus pandemic. Learn more at farmers.gov/coronavirus.

Coronavirus Interview with Sec. Alex Azar, Surgeon General Jerome Adams, Dr. Deborah Birx

“Our strategy is clear, which is we want to reduce the number of cases, we want to reduce the number of hospitalizations and we want to reduce the number of fatalities that result from coronavirus because we as the Surgeon General said, are weeks to months away from monoclonal antibodies allow us to treat and prevent the disease, as well as vaccines will enable us to as the President said, move beyond COVID, eventually, and we need to bridge to that. We need the American people to hang in there with us and our message about what they need to do is very clear, it’s wash your hands, watch your distance, wear your face covering when you can’t watch your distance, out of settings and you can’t do those things, and especially right now.” – Sec. Alex Azar

FDA Approves First Treatment for COVID-19

“The FDA is committed to expediting the development and availability of COVID-19 treatments during this unprecedented public health emergency,” said FDA Commissioner Stephen M. Hahn, M.D. “Today’s approval is supported by data from multiple clinical trials that the agency has rigorously assessed and represents an important scientific milestone in the COVID-19 pandemic. As part of the FDA’s Coronavirus Treatment Acceleration Program, the agency will continue to help move new medical products to patients as soon as possible, while at the same time determining whether they are effective and if their benefits outweigh their risks.”

NIH: Two Studies Show COVID-19 Antibodies Persist for Months

The new findings show that people who survive a COVID-19 infection continue to produce protective antibodies against key parts of the virus for at least three to four months after developing their first symptoms. In contrast, some other antibody types decline more quickly. The findings offer hope that people infected with the virus will have some lasting antibody protection against re-infection, though for how long still remains to be determined.

COVID-19 Vaccines: Planning for Equitable Distribution and Access

Duke Margolis Center for Health Policy
As part of Operation Warp Speed, initial planning is already underway for a staged distribution of an eventual vaccine. Under the leadership of the Centers for Disease Control (CDC) and the Department of Defense (DOD), the Federal government has outlined a process by which a centralized distribution system will support allocation of vaccines to critical and high-risk populations across all states and territories. As with any routine or seasonal vaccine, states and territories have responsibility for the “last mile” of vaccine distribution and administration— managing state systems for vaccine allocation, ordering, distribution, and inventory management, as well as working with providers across the state to deliver vaccines to the public across a wide variety of settings.

Updates for Children, Teens, and Young Adults

Updated guidelines include a Decision Making Tool to help parents and caregivers weigh the risks and benefits of their options as well as a Checklist for Families to help weigh the risks and benefits of their options.

COVID-19 Vaccines: Ensuring Regulatory and Scientific Integrity During the Approval Process

Duke Margolis Center for Health Policy
In recent weeks, career officials at the FDA have repeatedly made clear that they will not authorize or approve a COVID-19 vaccine without strong data showing that it is safe, effective, and manufactured to a high-quality standard. The process by which the FDA’s expert review staff and independent advisors will make this determination is based in decades of well-established regulatory processes, including multiple public-facing steps to ensure transparency. All of these steps will take place regardless of whether a vaccine is under review for full approval under a traditional BLA or for authorization under an EUA.

FDA Chief on Coronavirus Vaccine: 'No Corners Are Being Cut'

The emergency use authorization process tends to take a shorter amount of time, and will in this case — not because we'll skip steps, but because we've been working with the companies ahead of time on the various components of their application. The major difference between the two applications is that the standard for EUA approval looks for effectiveness and that the vaccine's benefits outweigh the risks. And then the last part of that, in terms of the authorization or approval process, is that we plan to have a vaccine advisory committee, which is a group of outside experts who will look at the data with us. We will ask them a series of questions and they will give us their opinion about the safety and effectiveness — and that is an open process, so the American public can see the data that we've given the committee and the questions raised.

Greatest COVID Accomplishments: What Wasn’t Done

Foreign leaders across the world have treated the coronavirus as an opportunity for unprecedented power grabs. China and South Korea track their citizens digitally. Israel suspended some courts. Hungary’s executive seized emergency authorities. Elections were delayed. Domestically, governors banned children from going to school, banned people from going to church, and closed businesses for weeks and months at a time.

🎬 VIDEO: Phase 3 clinical trial for a vaccine

NIH Director Dr. Francis Collins, National Institute of Allergy and Infectious Diseases (NIAID) Director Dr. Anthony Fauci, and COVID-19 Prevention Network Director of Community Engagement Dr. Michele Andrasik discussed the launch of a Phase 3 clinical trial for a vaccine to prevent COVID-19, as well as other vaccine research underway.

FDA’s Vaccines and Related Biological Products Advisory Committee and its Role in Advising the Agency on COVID-19 Vaccines

The development of safe and effective vaccines to prevent SARS-CoV-2 infection and/or COVID-19 is essential to help bring the pandemic under control.

COVID-19 Vaccine Appears Well-Tolerated and Effective in Developing Antibodies in Small Study of Older Adults

NIH Director Dr. Francis Collins released a blogpost on vaccine effectiveness in older adults. Recent findings show encouraging results from an early Phase 1 clinical trial that was expanded to include 40 adults over age 55.

NIH Clinical Trial Testing Hyperimmune Intravenous Immunoglobulin Plus Remdesivir to Treat COVID-19 Begins

A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun.

HHS Secretary Azar Delivers Remarks on Operation Warp Speed at Goldman Sachs Healthcare Virtual Event

“Pending FDA authorizations, we believe we may have up to 100 million doses by the end of the year—enough to cover especially vulnerable populations—and we project having enough for every American who wants a vaccine by March to April 2021... Every single day, I grow more confident that we will achieve the most important goal of Operation Warp Speed: delivering substantial quantities of a safe and effective vaccine by the end of this year.”

FDA Coronavirus (COVID-19) Update Daily Roundup

The U.S. Food and Drug Administration continues to announce actions taken in its ongoing response effort to the COVID-19 pandemic. As of today, 278 tests are authorized by FDA under EUAs; these include 217 molecular tests, 55 antibody tests, and 6 antigen tests.

Tell Me More About Vaccines – Video Episode 1 | National Institutes of Health

Right now, researchers and scientists, with the full support of the US government, are racing against the clock to develop a safe and efficacious vaccine against the virus and the disease it causes, COVID-19. Learn what makes vaccines so important, and how history, science, experience, and ingenuity all point to the eventual development of one or more successful vaccines against the coronavirus.

CDC: Updated Guidance on How COVID-19 Spreads

CDC updated its guidance on how COVID-19 spreads and includes information about the potential for the airborne spread of the SARS-CoV-2 (the virus that causes COVID-19). This update acknowledges the existence of some reports showing limited, uncommon circumstances where people with COVID-19 infected others who were more than 6 feet away or shortly after the COVID-19-positive person left an area. In these instances, transmission occurred in poorly ventilated and enclosed spaces that often involved activities that caused heavier breathing, like singing or exercise.

FDA Issues Guidance on Emergency Use Authorization for COVID-19 Vaccines

The U.S. Food and Drug Administration issued guidance with recommendations for vaccine sponsors regarding the scientific data and information that would support the issuance of an emergency use authorization (EUA) for an investigational vaccine intended to prevent COVID-19.

Coronavirus Food Assistance Program

President Trump and U.S. Secretary of Agriculture Sonny Perdue announced on September 17 that USDA will implement an expansion of the Coronavirus Food Assistance Program. Coronavirus Food Assistance Program 2, CFAP 2, will provide producers with financial assistance that gives them the ability to absorb some of the increased marketing costs associated with the COVID-19 pandemic.
• CFAP 2 follows the first round of CFAP, which had an application period of May 26 through September 11. You can learn more about USDA’s initial Coronavirus Food Assistance Program by visiting farmers.gov/cfap1.
• Producers can apply for assistance beginning Sept. 21, 2020. Applications will be accepted through Dec. 11, 2020.
• Additional information and application forms can be found at farmers.gov/cfap. Documentation to support the producer’s application and certification may be requested. All other eligibility forms, such as those related to adjusted gross income and payment information, can be downloaded from farmers.gov/cfap/apply.
• For existing FSA customers, including those who participated in CFAP 1, many documents are likely already on file. Producers should check with FSA county office to see if any of the forms need to be updated.
• In addition to CFAP 2, USDA has other programs and services available to farmers impacted by the coronavirus pandemic. Learn more at farmers.gov/coronavirus.

Framework for Equitable Allocation of COVID-19 Vaccine

The final report was released and includes recommendations for ensuring equity in distribution and access to the vaccine.

HHS Secretary Azar Statement on Mental Health Executive Order


"We know that the COVID-19 pandemic has created or exacerbated serious behavioral health challenges for many Americans, both adding new stresses and disrupting access to treatment. The President's Executive Order is a welcome opportunity to increase efforts to address the mental health effects of the pandemic, which have already included hundreds of millions of dollars in grants and historic flexibilities to ensure Americans can continue to receive treatment for mental illness and substance use disorders." HHS Secretary Alex Azar

House Select Subcommittee on the Coronavirus Crisis testimony

Today, Secretary of Health and Human Services Azar testified before House Select Subcommittee on the Coronavirus Crisis on the distribution of a safe and effective vaccine through Operation Warp Speed.
• On January 7, long before China had even admitted that human-to-human transmission was occurring, NIH researchers began vaccine development planning with Moderna.
• On Saturday, January 11, the morning after the viral sequence was finally shared by Chinese researchers, NIH scientists began work on that vaccine, which entered human trials on March 16.
• On February 3, with just 11 cases in the United States, BARDA began obligating flexible funds to go to private partners to support vaccine and therapeutic development.
• The next day, HHS made the first therapeutic funding announcement, to help Regeneron develop a therapeutic from monoclonal antibodies, which is now in Phase 3 trials.

Trump Adminstration Deploys Abbott BinaxNOW Tests to States

"This distribution of tens of millions of rapid tests is the fruit of President Trump's effective national testing strategy, which draws on the best of the public and private sectors," said HHS Secretary Alex Azar. "Coordination among FDA, private test developers, federal public health leaders, and state leadership has allowed us to build the world's largest and most effective testing system, supplying the right tests for the right circumstances."

COVID-related Donations

Donate COVID-19 Plasma
• If you have fully recovered from COVID-19, you may be able to help patients currently fighting the infection by donating your plasma. Because you fought the infection, your plasma now contains COVID-19 antibodies. These antibodies provided one way for your immune system to fight the virus when you were sick, so your plasma may be able to be used to help others fight off the disease. Learn more here.
• To find where you can donate source plasma, visit donatingplasma.org.

Donate Blood
• The COVID-19 pandemic has caused unprecedented challenges to the U.S. blood supply. Donor centers have experienced a dramatic reduction in donations due to the implementation of social distancing and the cancellation of blood drives. Blood is needed every day to provide lifesaving treatments to a variety of patients. You can help ensure that blood continues to be available for patients by finding a blood donor center near you to schedule your donation. Learn more here.
• To find where you can donate blood, visit aabb.org.

Donate Supplies and Equipment
• If you represent a business that would like to donate medical supplies, equipment or pharmaceuticals, please provide details on what you would like to give. This form is for donations only (click on button).

CARES Act Provider Relief Fund

Today, under President Trump’s leadership, HHS announced $20 billion in new provider relief funding for healthcare heroes on the frontlines of the coronavirus pandemic.
CARES Act Provider Relief Fund:
• The CARES Act, the Paycheck Protection Program, and Health Care Enhancement Act allocated $175 billion in relief funds to hospitals and other healthcare providers.
• The Provider Relief Funds support American families, workers, and the heroic healthcare providers in the battle against the COVID-19 outbreak.
• Under the Phase 3 General Distribution allocation, eligibility is expanded to also include behavioral health providers confronting the emergence of increased mental health and substance use issues exacerbated by the pandemic and providers who began practicing in 2020.

White House update

Today, the Trump Administration took action to evaluate and increase COVID-19 testing for underserved communities. The National Institutes of Health awarded approximately $234 million to expand COVID-19 testing for underserved and vulnerable populations. As a part of the Rapid Acceleration of Diagnostics (RADx) initiative, the RADx Underserved Populations (RADx-UP) program will support 32 institutions across the United States and will focus on populations disproportionately impacted by the pandemic. The program aims to gain a better understanding of COVID-19 testing patterns among underserved and vulnerable populations, strengthen the data on disparities in infection rates, disease progression, and outcomes, and develop strategies to reduce these disparities in COVID-19 testing.

CLI Update: COVID-19 Vaccine Candidates and Abortion-Derived Cell Lines

One concern regarding the ethical assessment of viral vaccine candidates is the potential use of abortion-derived cell lines in the development, production or testing of a vaccine. This analysis utilizes data from the primary scientific literature when available, along with data from clinical trial documents, reputable vaccine tracking websites, and published commercial information.1 It is the hope that by providing accurate data, recipients can make well-informed decisions regarding vaccine choices.

Trump Announces Distribution of 150m Rapid Coronavirus Tests

“President Trump announced on Monday that his administration will distribute 150 million Abbott coronavirus tests that produce results in just 15 minutes,” Cassidy Morrison writes for the Washington Examiner. “Trump said that 50 million tests would go to the most vulnerable communities: 18 million to nursing homes, 15 million to assisted living facilities, 10 million for hospice care providers, and nearly 1 million to historically black colleges and universities and colleges in tribal nations. Another 100 million tests will be allocated to states and territories to support efforts to reopen their economies and schools.”

Farmers to Families Food Box Program

Today, USDA announced that the Farmers to Families Food Box Program has distributed over 100 million food boxes supporting American farmers and families impacted by the COVID-19 pandemic.
• “With 100 million Farmers to Families Food Boxes delivered, we have utilized critical funding authorized by President Trump to continue connecting our great American farmers to millions of food insecure families. I am proud of this Administration’s mission to keep our most vulnerable families fed and support American family farms in the process.” - Advisor to the President, Ivanka Trump
• The Farmers to Family Food Box Program partners with national, regional, and local distributors, whose workforces have been significantly impacted by the closure of restaurants, hotels, and other food service businesses, to purchase up to $4 billion in fresh produce, dairy, and meat products from American producers of all sizes.
• Distributors package boxes of fresh fruits and vegetables, dairy products, and meat products into family-sized boxes, then transport them to food banks, community and faith-based organizations, and other non-profits serving Americans in need.
• Through the Farmers to Families Food Box Program, the Trump Administration is supporting over 200 farms and distributors and over 5,000 American jobs.

White House update

Today, President Trump gave an update on the Nation’s Coronavirus Testing Strategy and announced the deployment of 150 million rapid point-of-care tests across the country. Through public-private partnership, the Trump Administration is revolutionizing the coronavirus fight by equipping states with life-saving tests that will help ensure their communities are safe as schools and economies reopen. Under President Trump’s leadership, the Unites States has:
• Completed over 111 million COVID-19 tests and has the capacity to do 3 million tests a day;
• Delivered rapid testing devices to nearly 14,000 certified nursing homes;
• Opened over 1,000 community testing sites in low-income communities;
• Invested an unprecedented $8 billion to help tribal communities have the tests and resources they need to combat the virus; and
• Produced 150,000 ventilators for the Strategic National Stockpile.

HHS update

Fourth Large-Scale COVID-19 Vaccine Trial Begins in the United States
NIH announced that Johnson and Johnson's COVID-19 vaccine entered Phase 3 of their clinical trial. This is the 4th vaccine to enter Phase 3 clinical trials in the U.S. The trial is designed to evaluate if the investigational Janssen COVID-19 vaccine (JNJ-78436725) can prevent symptomatic COVID-19 after a single dose regimen. Up to 60,000 volunteers will be enrolled in the trial at nearly 215 clinical research sites in the United States and internationally. Enrollment diversity in the trials is crucial.

FDA update

The FDA issued an updated FDA COVID-19 Response At-A-Glance Summary which provides a quick look at facts, figures and highlights of the agency's response efforts.
Testing updates:
As of today, 255 tests are authorized by FDA under EUAs; these include 204 molecular tests, 47 antibody tests, and 4 antigen tests.

Johnson & Johnson Launches Massive Human Trial of COVID-19 Vaccine

Source: The Washington Times
The Janssen Pharmaceutical Companies of J&J said it plans to enroll up to 60,000 adults at nearly 215 clinical research sites in the U.S. and abroad. The company said its version offers twin advantages over some of their competitors — it can be delivered in a single dose and doesn’t require unusually cold storage temperatures. The Trump administration, through its “Operation Warp Speed,” is offering unprecedented support to private drugmakers as it tries to lock down a successful vaccine before the end of the year.

NIH Expands Clinical Trials to Test Convalescent Plasma against COVID-19

Two randomized, placebo-controlled clinical trials funded by the National Institutes of Health (NIH) are expanding enrollment to further evaluate convalescent plasma as a treatment for patients hospitalized with COVID-19. Preliminary observational studies indicate that convalescent plasma may improve outcomes among severely ill and hospitalized patients with COVID-19. Prospective, well-controlled randomized trials are needed to generate sufficient data on whether convalescent plasma is effective and safe for the treatment of COVID-19.

White House update

Today, President Trump delivered remarks to the 75th session of the United Nations General Assembly. President Trump discussed his Administration’s aggressive mobilization of ventilators, the progress being made in vaccine clinical trials, and vowed to hold China accountable.
• The United States launched the most aggressive mobilization since the Second World War and rapidly produced a record supply of ventilators, creating a surplus that allowed us to share them with friends and partners all around the globe.
• We pioneered life-saving treatments, reducing our fatality rate 85 percent since April.
• Three vaccines are in the final stage of clinical trials and are being mass-produced in advance so they can be delivered immediately upon arrival.

Vice President and Task Force briefing

Yesterday, Vice President Pence and the White House Coronavirus Task Force briefed governors on the Administration’s COVID-19 response, the Strategic National Stockpile (SNS) modernization efforts, and supply chain stability, including replenishing State and federal stockpiles. The Vice President also discussed best practices with our Nation’s governors on limiting Coronavirus spread, including protecting our most vulnerable citizens in nursing homes, leveraging our testing ecosystem, safely reopening America’s schools, Operation Warp Speed’s efforts to safely develop and distribute a vaccine, and encouraging Americans to adhere to State and local guidelines and to wear face coverings when social distancing cannot be maintained.

COVID-19 Partner Update: CDC COVID-19 Vaccination Planning: What You Should Know

Monday, September 21, 2020, 3:00 – 4:00 PM (ET)
Join CDC subject matter experts for an update on what you and your community should know about the CDC’s COVID-19 response and the vaccine program. Speakers include:
• Dr. John Brooks, Chief Medical Officer for the CDC COVID-19 Emergency Response
• Dr. Nancy Messonnier, Director of the COVID-19 Vaccine Planning Unit
• Dr. Diane Hall, Deputy for Partnerships and Risk Management, CDC COVID-19 Emergency Response (Moderator)
The CDC encourages submitting questions in advance. Please email eocevent337@cdc.gov with "Partner Call 9/21" in the subject line. The call will be recorded and posted on CDC's website.

Flu Vaccine Essential during COVID-19 Pandemic

Not only is flu season about to begin, the COVID-19 pandemic is still in full swing, further stressing the importance of the flu vaccine. The vaccine could help reduce the overall impact of contagious respiratory illnesses on the population and decrease the burden on the health care system during the overlapping flu season and COVID-19 pandemic.

HHS Update: Trump Administration Release COVID-19 Vaccine Distribution Strategy

“As part of Operation Warp Speed, we have been laying the groundwork for months to distribute and administer a safe and effective COVID-19 vaccine as soon as it meets FDA’s gold standard,” said HHS Secretary Alex Azar. “This in-depth, round-the-clock planning work with our state and local partners and trusted community organizations, especially through CDC, will ensure that Americans can receive a safe and effective vaccine in record time.”

COVID DEVELOPMENTS -- Department of Defense: Operation Warp Speed

Under the leadership of President Trump and using the resources of the federal government and the U.S. private sector, Operation Warp Speed (OWS) will accelerate the testing, supply, development, and distribution of safe and effective vaccines, therapeutics, and diagnostics to counter COVID-19 by January 2021. OWS is leveraging the best, most talented experts from across the federal government and private industry to develop safe and effective vaccines and therapeutics quickly without compromising safety.

Coronavirus Food Assistance Program 2

President Trump and U.S. Secretary of Agriculture Sonny Perdue announced on September 17 that USDA will implement an expansion of the Coronavirus Food Assistance Program. Coronavirus Food Assistance Program 2, CFAP 2, will provide producers with financial assistance that gives them the ability to absorb some of the increased marketing costs associated with the COVID-19 pandemic.
• CFAP 2 follows the first round of CFAP, which had an application period of May 26 through September 11. You can learn more about USDA’s initial Coronavirus Food Assistance Program by visiting farmers.gov/cfap1.
• Producers can apply for assistance beginning Sept. 21, 2020. Applications will be accepted through Dec. 11, 2020.
• Additional information and application forms can be found at farmers.gov/cfap. Documentation to support the producer’s application and certification may be requested. All other eligibility forms, such as those related to adjusted gross income and payment information, can be downloaded from farmers.gov/cfap/apply.
• For existing FSA customers, including those who participated in CFAP 1, many documents are likely already on file. Producers should check with FSA county office to see if any of the forms need to be updated.
• In addition to CFAP 2, USDA has other programs and services available to farmers impacted by the coronavirus pandemic. Learn more at farmers.gov/coronavirus.

Administration Releases COVID-19 Vaccine Distribution Strategy

Documents released yesterday by HHS and Department of Defense (DoD) provide a strategic distribution overview along with an interim playbook for state, tribal, territorial, and local public health programs and their partners on how to plan and operationalize a vaccination response to COVID-19 within their respective jurisdictions.

Coronavirus Commission for Safety and Quality in Nursing Homes’ findings

The Trump Administration remains committed to keeping nursing home residents safe and to providing transparency for the American people in the face of this unprecedented pandemic. Today, Vice President Pence held a roundtable on the Coronavirus Commission for Safety and Quality in Nursing Homes’ findings and general issues facing the Nation’s elder care system. More information on the Commission and their findings can be found here.
• The Coronavirus Commission for Safety and Quality in Nursing Homes is an independent Commission announced by President Trump in April 2020.
• The Commission is composed of leading industry experts, doctors and scientists, resident and patient advocates, family members, infection and prevention control specialists, and State and local authorities.
• The Commission conducted an independent review and comprehensive assessment of the nursing home response to the COVID-19 pandemic in order to identify opportunities for improvement and inform immediate and future action.
• The Trump Administration has already taken significant steps to implement many of the Commission’s findings.
o The Administration has worked to support nursing homes financially during this challenging time, distributing over $21 billion to America’s nursing homes – more than $1.5 million each on average.
o To ensure nursing homes had access to supplies, the Trump Administration shipped a 14-day supply of personal protective equipment (PPE) to more than 15,000 nursing homes across the Nation in May.
o The Administration has also required facilities to report data about COVID-19 cases, deaths, and supply levels, with 99.3 percent of facilities currently reporting.

4 doctors/congressmen: Coronavirus vaccine -- we'll get one and here's why we trust the science

Typically, vaccine development takes 10-15 years. Under Operation Warp Speed, the goal is to shorten that to 12-18 months and, remarkably, researchers are actually ahead of this already accelerated schedule. Manufacturing of vaccine doses is occurring at the same time that safety and efficacy tests are ongoing. Normally, such production would not occur until the FDA approval process is complete. These simultaneous timelines save months and years of production time, and thus help to ensure that once a vaccine is approved, millions of doses will be immediately ready for distribution, especially for the most vulnerable.

How to Help

Donate COVID-19 Plasma
• If you have fully recovered from COVID-19, you may be able to help patients currently fighting the infection by donating your plasma. Because you fought the infection, your plasma now contains COVID-19 antibodies. These antibodies provided one way for your immune system to fight the virus when you were sick, so your plasma may be able to be used to help others fight off the disease. Learn more here.
• To find where you can donate source plasma, visit donatingplasma.org.

Donate Blood
• The COVID-19 pandemic has caused unprecedented challenges to the U.S. blood supply. Donor centers have experienced a dramatic reduction in donations due to the implementation of social distancing and the cancellation of blood drives. Blood is needed every day to provide lifesaving treatments to a variety of patients. You can help ensure that blood continues to be available for patients by finding a blood donor center near you to schedule your donation. Learn more here.
• To find where you can donate blood, visit aabb.org.

Donate Supplies and Equipment
• If you represent a business that would like to donate medical supplies, equipment or pharmaceuticals, please provide details on what you would like to give. This form is for donations only.

Sell Supplies and Equipment
• If you are interested in doing business with FEMA with your company’s non-medical goods and/or services, submit your inquiry to the Department of Homeland Security (DHS) Procurement Action Innovative Response Team (PAIR) team at DHSIndustryLiaison@hq.dhs.gov.
• The federal government is purchasing medical supplies or equipment under the Defense Logistics Agency (DLA) Request for information (RFI). Visit the DLA website for more information.

Developing Medical Countermeasures
• If you would like to meet with a federal agency regarding a vaccine, diagnostic, therapeutic or other medical device that you are developing for SARS-CoV-2 or COVID-19, please go to medicalcountermeasures.gov.

Other Forms of Help
• If you or someone you know represent a hospital or healthcare provider in need of medical supplies, please contact your state, local, tribal or territory department of public health and/or emergency management agency.
• If you represent a private sector business and wish to learn more about getting involved in a way that is not listed here, please e-mail nbeoc@max.gov or visit our National Business Emergency Operations Center page.

For additional information, please visit FEMA’s website: www.fema.gov/coronavirus/how-to-help.

Trump Administration Releases COVID-19 Vaccine Distribution Strategy

The strategic overview lays out four tasks necessary for the COVID-19 vaccine program:
Engage with state, tribal, territorial, and local partners, other stakeholders, and the public to communicate public health information around the vaccine and promote vaccine confidence and uptake.
Distribute vaccines immediately upon granting of Emergency Use Authorization/ Biologics License Application, using a transparently developed, phased allocation methodology and CDC has made vaccine recommendations.
Ensure safe administration of the vaccine and availability of administration supplies.
Monitor necessary data from the vaccination program through an information technology (IT) system capable of supporting and tracking distribution, administration, and other necessary data.

NIH ACTIV Initiative Launches Adaptive Clinical Trials of Blood-Clotting Treatments for COVID-19 (HERE)

The National Institutes of Health has launched two of three adaptive Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19. Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, these trials will be conducted at more than 100 sites around the world and will involve patients in various clinical settings — those who have not been hospitalized, those currently hospitalized and those discharged after hospitalization for moderate to severe disease.

Administration Takes Action to Expand Access to COVID-19 Vaccines

Today, under the leadership of President Trump, the U.S. Department of Health and Human Services (HHS), through the Assistant Secretary for Health, issued guidance under the Public Readiness and Emergency Preparedness Act (PREP Act) to expand access to safe and effective COVID-19 vaccines when they are made available. This guidance authorizes state-licensed pharmacists to order and administer, and state-licensed or registered pharmacy interns acting under the supervision of the qualified pharmacist to administer, COVID-19 vaccinations to persons ages 3 or older, subject to certain requirements.

"This action builds upon our Administration's progress toward delivering a safe, effective, and widely available vaccine by 2021," said Assistant Secretary for Health ADM Brett P. Giroir, M.D. "Allowing pharmacists to order and administer COVID-19 vaccines will greatly expand convenient access for the American people."

White House Coronavirus Task Force update

Today, the White House Coronavirus Task Force participated in a bipartisan call with America’s Governors to discuss the ongoing COVID-19 response and recovery and delivered an update on Operation Warp Speed’s progress to develop, manufacture, and distribute a safe and effective COVID-19 vaccine. Additionally, under the leadership of President Trump, the U.S. Department of Health and Human Services (HHS) issued new guidance today to expand access to safe and effective COVID-19 vaccines when they are made available. This guidance authorizes state-licensed pharmacists to order and administer COVID-19 vaccinations to persons ages 3 or older, subject to certain requirements.

White House update

Today, the White House Coronavirus Task Force met to discuss vaccines in Phase 3 trials and plans for nationwide distribution. Under President Trump’s leadership of Operation Warp Speed, unprecedented progress on a safe and effective vaccine is being made. Using the resources of the federal government and the U.S. private sector, Operation Warp Speed (OWS) will accelerate the testing, supply, development, and distribution of safe and effective vaccines, therapeutics, and diagnostics to counter COVID-19 by January 2021.

How we're developing a COVID-19 vaccine at 'Warp Speed': Alex Azar

USA Today
Thanks to OWS, the entire process for delivering a safe and effective vaccine — to be assessed by FDA’s apolitical scientific experts just as any other vaccine would be — is underway and on track. We are immensely encouraged by the progress so far, and hope to celebrate the successful delivery of a safe and effective vaccine in large quantities in the months to come.

White House Update

President Trump and his Administration continue to use all federal resources available to fight COVID-19. We continue to see strong progress in the fight against coronavirus – with the 7-day average in new cases down 37% since its peak in July and nearly half of all jurisdictions are now in a downward trajectory in cases.

ALL OF AMERICA RESPONSE
• President Trump has lead the largest mobilization of public and private resources since WWII to respond to this pandemic.
• The Trump Administration has worked with private sector partners to secure the delivery of 99 million N95 respirators, 15 million face shields, 83 million gloves, and more.
o These critical PPE supplies are helping our heroes on the frontlines stay safe while saving lives.
• President Trump has taken around 80 DPA and DPA-related actions to ensure we have the supplies we need.
• Thanks to President Trump’s efforts, no American who has needed a ventilator has gone without one.
• President Trump has bolstered our strategic national stockpile to ensure we are prepared for any event that may come in the future.

WORLD-LEADING TESTING SYSTEM
• President Trump has built the world’s leading coronavirus testing system from scratch, with more than 88 million tests completed so far.
o Thanks to President Trump’s efforts, the United States has increased daily testing by 32,000% since mid-March.
o 94% of patients are receiving their test results back within just 3 days.
• The Administration is providing extensive testing support to states, including providing supplies.
• To date, surge testing has been deployed to 18 sites to help ramp up testing in local hot spots.
• In order to ensure all Americans have access to testing resources, 94% of Federally Qualified Health Centers now offer testing.
• In order to protect our seniors, more than 10,000 testing instruments and nearly 3 million tests have been shipped to nursing homes across the country.

DEVELOPING LIFE-SAVING VACCINES AND THERAPEUTICS
• President Trump’s Operation Warp Speed is making incredible progress in helping to rapidly develop a vaccine.
• Three strong vaccine candidates are already moving through phase three trials in the United States.
• The Trump Administration is investing billions to secure vaccine doses for the American people so they can be distributed as soon as a candidate is approved.
• The Administration is utilizing American innovation to develop new, innovative therapies and save lives.
• Over 270 clinical trials are currently underway for coronavirus treatments.

White House Update

The Trump Administration continues to take action to support and enable innovation, develop diverse group of tests to meet the needs of different communities, and scale manufacturing to increase testing accessibility. Today, the National Institutes of Health announced $129.3 million in scale-up and manufacturing support for a new set of COVID-19 testing technologies as part of the NIH’s Rapid Acceleration of Diagnostics (RADx) initiative.
• NIH is awarding contracts to nine companies for technologies that include portable point-of-care tests for immediate results and high-throughput laboratories that can return results within 24 hours.
• These new technologies collectively will significantly increase the number, type, and availability of tests by millions per week by this fall.

Trump Administration Announces Provider Relief Fund Application for Assisted Living Facilities

“HHS is committed to ensuring America’s healthcare providers have what they need to protect their patients and continue providing care through the pandemic,” said HHS Secretary Alex Azar. “By expanding the Provider Relief Fund to assisted living facilities, we are supporting more frontline providers and helping to protect the nearly 1 million vulnerable older Americans in their care.”

White House Update

Today, the Trump Administration delivered on its promise to rural Americans. On August 3, 2020, President Trump’s signed Executive Order on Improving Rural Health and Telehealth Access. The Federal Communications Commission (FCC), U.S. Department of Health and Human Services (HHS), and U.S. Department of Agriculture (USDA) announced that they have signed a Memorandum of Understanding to work together on the Rural Telehealth Initiative, a joint effort to collaborate and share information to address health disparities, resolve service provider challenges, and promote broadband services and technology to rural areas in America.
• As part of this Memorandum of Understanding, the agencies intend to establish an interagency Rural Telehealth Initiative Task Force comprised of representatives from each agency. This Task Force will regularly meet to consider future recommendations or guidelines for this effort and exchange agency expertise, scientific and technical information, data, and publications.
• The ongoing COVID-19 pandemic has highlighted the critical importance of telehealth in delivering quality healthcare to rural Americans, who are acutely affected by gaps in the healthcare system, from hospital closures to a lack of specialty care.
• Telemedicine plays an increasingly critical part in treating patients, improving health outcomes, lowering costs, and helping health care providers maximize their impact on their communities, especially in rural areas of the United States.

Trump Administration Will Deploy 150 Million Rapid Tests in 2020

Today, as part of an historic initiative led by the U.S. Department of Health and Human Services (HHS) and the Department of and Defense (DOD), the Administration awarded a contract for $760 million to Abbott for delivery of 150 million rapid, Abbott BinaxNOW COVID-19 Ag Card Point of Care (POC) SARS-CoV-2 diagnostic tests to expand strategic, evidence-based testing in the United States. Testing will be potentially deployed to schools and to assist with serving other special needs populations.

“The introduction of Abbott’s antigen test is another incredibly valuable result of President Trump’s all-of-America approach to constructing our world-leading COVID-19 testing capacity,” said HHS Secretary Alex Azar.

COVID Is Causing Increase in Suicidal Thoughts and Decrease in Mental Health

According to recent report from the Centers for Disease Control, “40 percent of American adults have reported struggling with mental health or substance abuse” during the COVID-19 pandemic. One-third reported feelings of anxiety and/or depression, and one-quarter said that they were struggling with trauma-related issues. One in eight reported either developing or increasing substance-abuse problems.

Worst of all, 11 percent reported that they seriously considered suicide in the last few months.

White House update

Nursing homes are now required to test their staff twice a week, weekly, or monthly, depending on local factors such as an individual facility’s risk for COVID-19 transmission. Residents and staff will also be tested when there are new cases. In order to make this required testing easier and less costly, the Trump Administration is providing point-of-care testing devices and an initial supply of test kits to nursing homes. The Trump Administration has already shipped over 2 million point-of-care tests and over 5,600 point-of-care machines to the highest risk nursing homes. The Trump Administration is also actively monitoring supplies at every nursing home and sending 1.5 million N95 masks to those that have reported shortages.

FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID–19 Treatment

Based on the scientific evidence available, the U.S. Food & Drug Administration (FDA) has issued an emergency use authorization (EUA) that investigational convalescent plasma be used for the treatment of COVID-19 in hospitalized patients. According to the FDA, this product may be effective in treating COVID-19 and the known and potential benefits of the product outweigh the known and potential risks of the product.

HHS Awards Over $35 million to Increase Access to High Quality Health Care in Rural Communities

“President Trump has made it a priority to strengthen rural health infrastructure and promote the health of rural Americans,” said HHS Deputy Secretary Eric Hargan. “As someone who grew up in rural America and with rural healthcare providers in my family, I know the challenges they face, and I know there’s a need for transformation. These awards are in line with the actions the President called for in his Executive Order on Improving Rural Health and Telehealth Access and are part of our overall effort to improve rural access to care in sustainable and innovative ways.”

Trump Administration Uses Defense Production Act to Aid Our Most Vulnerable

"The federal efforts to supply nursing homes with rapid point-of-care antigen instruments and tests is our highest priority to save lives and the US Government will exert its full authority to complete this mission. We are invoking the priority rating of the Defense Production Act to expedite shipments of instruments and antigen tests to give nursing homes the ability to perform these rapid tests. HHS will continue to explore every possible avenue to get life-saving supplies to the frontlines of this war on the virus.” Admiral Brett P. Giroir, M.D., Assistant Secretary for Health and COVID-19 Testing Coordinator.

The Trump Administration Strongly Supports Telehealth Innovation

“The onset of COVID-19 has challenged our Nation and the world to rethink the future of healthcare delivery. The Trump Administration is advancing our Nation’s health through a shared public and private sector commitment to emerging technologies that make high quality healthcare more accessible for all Americans,” U.S. Chief Technology Officer Michael Kratsios said.

Donate Blood

• The COVID-19 pandemic has caused unprecedented challenges to the U.S. blood supply. Donor centers have experienced a dramatic reduction in donations due to the implementation of social distancing and the cancellation of blood drives. Blood is needed every day to provide lifesaving treatments to a variety of patients. You can help ensure that blood continues to be available for patients by finding a blood donor center near you to schedule your donation.
• To find where you can donate blood, visit aabb.org.

Catholic Charities Pandemic Assistance Total Nearly $400 Million

“We are feeding more people than ever,” he said. Whereby in a typical month before the pandemic the program served between 5,000 and 7,000 people, agency statistics showed, the numbers rose significantly in the spring. In April it was 11,000, in May 21,000 and in June 25,000.

Assistance for Communities

Assistance for Communities
CARES Act Recovery Assistance Grants: The U.S. Department of Commerce’s Economic Development Administration (EDA) is awarding CARES Act Recovery Assistance Grants to assist communities in responding to the coronavirus pandemic. These grants are being administered under the authority of the bureau’s flexible Economic Adjustment Assistance (EAA) program, which provides a wide-range of financial assistance to eligible communities and regions as they respond to and recover from the impacts of the coronavirus pandemic.

White House update - mobilization

Today, President Trump held a news conference on his Administration’s historic industrial mobilization to ensure Americans have the necessary PPE to fight the coronavirus.
• Today, the Office of Trade and Manufacturing Policy released a new report on how the Trump Administration has harnessed the full power of the Defense Production Act to achieve the greatest industrial mobilization since World War Two.
• The administration has exercised the authority under the Defense Production Act and related authorities 78 times, dispersing over $3.5 billion to speed the development and manufacturing of essential materials.
• Since the start of the pandemic, we have tripled the number of N95 masks on hand to over 40 million, tripled the number of gowns to over 15 million, and quadrupled the number of ventilators to 69,000.
• By September, the Strategic National Stockpile inventory is on track to contain over 300 million N95 respirators and surgical masks, over 4.5 billion gloves, and over 190,000 ventilators.
• The federal government is collaborating with McKesson Corporation, a central distributor of future COVID-19 vaccines and related supplies needed to administer the vaccinations, to rapidly distribute a coronavirus vaccine as soon as one is approved.
• We currently have three candidates in phase three clinical trials and are on pace to have more than 100 million doses of a vaccine ready before the end of the year and 500 million doses very shortly thereafter.

Donate blood

Donate Blood
• The COVID-19 pandemic has caused unprecedented challenges to the U.S. blood supply. Donor centers have experienced a dramatic reduction in donations due to the implementation of social distancing and the cancellation of blood drives. Blood is needed every day to provide lifesaving treatments to a variety of patients. You can help ensure that blood continues to be available for patients by finding a blood donor center near you to schedule your donation.

White House update - vaccines

• Today, President Trump announced an agreement with Moderna to manufacture and deliver 100 million doses of their coronavirus vaccine candidate.
• Recently, we also secured partnerships with Johnson & Johnson, as well as Sanofi and GlaxoSmithKline, to support the large-scale manufacturing of their vaccines.
• Three vaccine candidates are now in phase three trials already – the final stage of clinical trials.
• We are investing in the development and manufacture of the top six vaccine candidates to ensure rapid delivery and are on track to rapidly produce 100 million doses as soon as the vaccine is approved, and up to 500 million shortly thereafter.
• We’ve treated more than 86,000 Americans with convalescent plasma.
• The United States has now conducted more than 66 million tests, far more than any other nation in the world.
• Protecting our nursing home residents remains a critical focus for the Trump Administration. HHS recently announced that they will use the provider relief fund to deliver an additional $5 billion dollars to further protect nursing homes and long-term care facilities as they continue to combat the coronavirus.
• We have delivered over 1800 rapid point-of-care testing devices to nursing homes and we are in the process of delivering these devices to all 15,000 Medicare and Medicaid certified nursing homes by the end of September.
• 87% of the counties in the United States reported declining cases.
• Mortality has declined by 7% and hospitalizations are declining rapidly.
• States that were primary hotspots such as Florida, Texas, and Arizona have reduced cases by nearly 25%.
• Since the end of July, the seven-day average for cases in the United States has fallen by nearly 20%.

White House update - schools

Today, President Trump participated in a forum on getting America’s children safely back to school. President Trump continues to be committed to helping schools safely reopen for the wellbeing of America’s children and has already dedicated significant resources and efforts to support our schools. Fact sheet: https://www.whitehouse.gov/briefings-statements/president-donald-j-trump-supporting-americas-students-families-encouraging-safe-reopening-americas-schools/

Donating plasma

Donate COVID-19 Plasma
• If you have fully recovered from COVID-19, you may be able to help patients currently fighting the infection by donating your plasma. Because you fought the infection, your plasma now contains COVID-19 antibodies. These antibodies provided one way for your immune system to fight the virus when you were sick, so your plasma may be able to be used to help others fight off the disease. Learn more here.
• To find where you can donate source plasma, visit donatingplasma.org.

White House update

Today, both President Trump and Press Secretary Kayleigh McEnany provided an update on the Administration’s COVID-19 efforts.
• In the last seven days, nationwide cases declined by 14%, hospitalizations decreased by 7%, and fatalities decreased by 9%.
• President Trump built the world’s leading testing system from nothing, based on a virus we have never faced before. To date, we have already conducted more than 65 million tests, far outpacing any other country.
• The Administration continues to take actions to protect the most vulnerable populations in nursing homes and senior citizens areas. We have delivered over 1,800 rapid point-of-care testing devices and shipped over 700,000 tests to nursing homes.
• This weekend, President Trump took executive action designed to provide relief to those who need it most. Through four executive orders, he took the following steps:
o On the payroll tax, he deferred payments of the employee portion of certain payroll taxes from September 1st through the end of 2020.
o On unemployment assistance, states will provide 25 percent cost sharing, amounting to a total of $400 per week in benefits through the end of the year.
o He extended eviction protections by directing HUD to prevent evictions resulting from financial hardships caused by the virus, doing everything in his executive capacity to make sure renters and homeowners are protected.
o Finally, on student loans, he extended 0 percent interest and suspended loan payments through the end of the year.

Proposal to Expand Telehealth Benefits Permanently for Medicare Beneficiaries and Advances in Access to Care in Rural Areas


The Centers for Medicare & Medicaid Services (CMS) is proposing changes to expand telehealth permanently, consistent with the Executive Order on Improving Rural and Telehealth Access.

Donate Blood

• The COVID-19 pandemic has caused unprecedented challenges to the U.S. blood supply. Donor centers have experienced a dramatic reduction in donations due to the implementation of social distancing and the cancellation of blood drives. Blood is needed every day to provide lifesaving treatments to a variety of patients. You can help ensure that blood continues to be available for patients by finding a blood donor center near you to schedule your donation.

FDA Commissioner: “No Matter What, Only A Safe, Effective Vaccine Will Get Our Approval”

This Op-ed by Dr. Stephen Hahn, FDA Commissioner, writes about the large-scale clinical trials already have begun for several promising vaccine candidates and what information the FDA will require to decide whether approval of the vaccine for general use is justified.

CDC Updated Toolkit for Young Adults – 15 to 21


Resources and tools designed for youth and young adults to keep them healthy as they venture out.

Assistance for Communities


CARES Act Recovery Assistance Grants: The U.S. Department of Commerce’s Economic Development Administration (EDA) is awarding CARES Act Recovery Assistance Grants to assist communities in responding to the coronavirus pandemic. These grants are being administered under the authority of the bureau’s flexible Economic Adjustment Assistance (EAA) program, which provides a wide-range of financial assistance to eligible communities and regions as they respond to and recover from the impacts of the coronavirus pandemic.

White House news conference

Today, President Trump held a news conference on COVID-19, where he announced plans to retroactively cut payroll taxes from July 1st through the end of year, enhance unemployment benefits through the end of the year, defer student loan payments and forgive interest until further notice, and extend the eviction moratorium.

Phase 3 Clinical Trial of Investigational Vaccine for COVID-19 Begins


A Phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent COVID-19 in adults has begun. The vaccine was co-developed by the biotechnology company Moderna, Inc. and the National Institutes of Health (NIH). The trial, to be conducted at 89 U.S. clinical research sites, is expected to enroll approximately 30,000 adult volunteers who do not have COVID-19. (See next item)

  • Facebook Social Icon
  • Twitter Social Icon

©2020 Freedom2Care and Christian Medical Association – All Rights Reserved

P.O. Box 76088 • Washington, DC • 20013

Info@Freedom2Care.org